Form 4: Provectus Biopharmaceuticals CEO Acquires Convertible Promissory Note and Preferred Stock

CEO Edward Pershing reports acquisition of an unsecured convertible promissory note and Series D-1 Convertible Preferred Stock in Provectus Biopharmaceuticals' 2025 Financing.

Summary

• Edward Pershing, CEO of Provectus Biopharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates Pershing acquired an 8% unsecured convertible promissory note for $50,000 on May 7, 2025, convertible to Series D-1 Preferred Stock at $2.862 per share.
• Pershing also owns 17,471 shares of Series D-1 Convertible Preferred Stock.
• The promissory note will automatically convert into Series D-1 Preferred Stock on May 7, 2026.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock and will automatically convert on June 26, 2026, unless converted earlier.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Future Outlook

The promissory note will automatically convert into Series D-1 Preferred Stock on May 7, 2026, and the Series D-1 Preferred Stock will automatically convert into Common Stock on June 26, 2026, unless converted earlier.

Industry Context

This filing is a routine disclosure of insider transactions, providing transparency to investors regarding the holdings and transactions of company executives. It is common for executives to hold convertible securities as part of their compensation or investment strategy.

Stakeholder Impact

• Shareholders are informed about the CEO's investment in the company through the acquisition of the convertible note and preferred stock.

Key Dates

Keywords

Form 4, beneficial ownership, convertible note, preferred stock, Provectus Biopharmaceuticals, PVCT, Edward Pershing